Join
Live feed
·
PRReleasevia Quantisnow
Exelixis Inc. logo
Zymeworks Inc. logo

Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application

ByQuantisnow·Wall Street's wire, on your screen.
EXEL· Exelixis Inc.ZYME· Zymeworks Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EXEL (Exelixis Inc.), ZYME (Zymeworks Inc.) and more on Quantisnow.